Biochemical risk factors of atherosclerotic cardiovascular disease: from a narrow and controversial approach to an integral approach and precision medicine

References

• Ference BA, Ginsberg HN, Graham I, et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 38(32): 2459–2472. 2017.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
   PubMed Web of Science ®Google Scholar
• Ravnskov U, de Lorgeril M, Diamond DM, et al. LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature. Expert Rev Clin Pharmacol. 2018;11(10):959–970.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289–1297.
   PubMed Web of Science ®Google Scholar
• DuBroff R. A reappraisal of the lipid hypothesis. Am J Med. 2018;131:993–997.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40:2760–2770.
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol Ther. 2014;141:358–367.
   PubMed Web of Science ®Google Scholar
• Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet. 2020;396:1644–1652.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Lonn E, Paynter NP, et al. Primary prevention with statin therapy in the elderly: new meta-analyses from the contemporary jupiter and HOPE-3 randomized trials. Circulation. 2017;135(20):1979–1981.
   PubMed Web of Science ®Google Scholar
• Gencer B, Marston NA, Im KA, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637–1643.
   PubMed Web of Science ®Google Scholar
• Postmus I, Deelen J, Sedaghat S, et al. LDL cholesterol still a problem in old age? A Mendelian randomization study. Int J Epidemiol. 2015;44(2):604–612.
   PubMed Web of Science ®Google Scholar
• Iversen A, Jensen JS, Scharling H, et al. Hypercholesterolaemia and risk of coronary heart disease in the elderly: impact of age: the Copenhagen City Heart Study. Eur J Intern Med. 2009;20(2):139–144.
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Islam S, McQueen M, et al. Age and cardiovascular risk attributable to apolipoprotein B, low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol. J Am Heart Assoc. 2016;5(10):e003665.
   PubMed Web of Science ®Google Scholar
• Bathum L, Christensen RD, Pedersen LE, et al. Association of lipoprotein levels with mortality in subjects aged 50+ without previous diabetes or cardiovascular disease: a population-based register study. Scand J Prim Health Care. 2013;31(3):172–180.
   PubMed Web of Science ®Google Scholar
• Armitage J, Baigent C, Barnes E, Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415.
   PubMed Web of Science ®Google Scholar
• Ulmer H, Kelleher C, Diem G, et al. Why Eve is not Adam: prospective follow-up in 149650 women and men of cholesterol and other risk factors related to cardiovascular and all-cause mortality. J Womens Health. 2004;13(1):41–53.
   Web of Science ®Google Scholar
• Hamazaki T, Okuyama H, Ogushi Y, et al. Towards a paradigm shift in cholesterol treatment. A re-examination of the cholesterol issue in Japan. Ann Nutr Metab. 2015;66(suppl 4):1–116.
   PubMedGoogle Scholar
• Zhou L, Wu Y, Yu S, et al. Low-density lipoprotein cholesterol and all-cause mortality: findings from the China health and retirement longitudinal study. BMJ Open. 2020;10(8):e036976.
   PubMed Web of Science ®Google Scholar
• Zeng L, Ye Z, Li Y, et al. Different lipid parameters in predicting clinical outcomes in Chinese statin-naïve patients after coronary stent implantation. Front Cardiovasc Med. 2021;8:638663.
   PubMed Web of Science ®Google Scholar
• Hero C, Svensson A-M, Gidlund P, et al. LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes. Diabetes Medicine. 2016;33(3):316–323.
   PubMed Web of Science ®Google Scholar
• Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008;371:1800–1819.
   PubMed Web of Science ®Google Scholar
• Hirany S, O’Byrne D, Devaraj S, et al. Remnant-like particle cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem. 2000;46(5):667–672.
   PubMed Web of Science ®Google Scholar
• Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials, an analysis of end point postponement. BMJ Open. 2015;5(9):e007118.
   PubMed Web of Science ®Google Scholar
• DuBroff R, De Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015;7(7):404–409.
   PubMed Web of Science ®Google Scholar
• Brown RE, Welsh P, Logue J. Systematic review of clinical guidelines for lipid lowering in the secondary prevention of cardiovascular disease events. BMJ Open Heart. 2020;7(2):e001396.
   PubMed Web of Science ®Google Scholar
• DuBroff R, Malhotra A, De Lorgeril M. Hit or miss: the new cholesterol targets. BMJ Evid Based Med. 2021;26:271–278.
   Google Scholar
• Matsuzaki M, Kita T, Mabuchi H, et al. Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy in Japanese patients with hypercholesterolemia. Circ J. 2002;66(12):1Page No:10 087–1095.
   Web of Science ®Google Scholar
• Pacelli F, Doglietto GB, Alfieri S, et al. Prognosis in intra-abdominal infections. Multivariate analysis on 604 patients. Arch Surg. 1996;131(6):641–645.
   PubMedGoogle Scholar
• Zhao M, Luo Z, He H, et al. Decreased low-density lipoprotein cholesterol level indicates poor prognosis of severe and critical COVID-19 patients: a retrospective, single-center study. Front Med (Lausanne). 2021;8:585851.
   PubMed Web of Science ®Google Scholar
• Wei X, Zeng W, Su J, et al. Hypolipidemia is associated with the severity of COVID-19. J Clin Lipidol. 2020;14(3):297–304.
   PubMed Web of Science ®Google Scholar
• Netea MG, Demacker PN, Kullberg BJ, et al. Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest. 1996;97(6):1366–1372.
   PubMed Web of Science ®Google Scholar
• Sijbrands EJ, Westendorp RG, Defesche JC, et al. Mortality overtwo centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ. 2001;322:1019–1023.
   PubMed Web of Science ®Google Scholar
• Diamond DM, Ravnskov U. How statistical deception created the appearance that statins are safe and effective in primary and secondary prevention of cardiovascular disease. Expert Rev Clin Pharmacol. 2015;8(2):201–210.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• Collins R. Post truth medicine: death and disability by disinformation. Anitschkov lecture presented at the Scientific Sessions of the European Atherosclerosis Society. Helsinki. 2021.
   Google Scholar
• Cholesterol Treatment Trialists’ Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–1405.
   PubMed Web of Science ®Google Scholar
• De Backer GG. Editorial: statin therapy in the elderly: less or more? Eur J Prev Cardiol. 2021. Online ahead of print. DOI: https://doi.org/10.1093/eurjpc/zwaa164.
   Google Scholar
• Gitsels LA, Bakbergenuly I, Steel N, et al. Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records. Fam Med Com Health. 2021;9(2):e000780.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24(10):1057–1066.
   PubMed Web of Science ®Google Scholar
• Mercep I, Radman I, Trkulja V, et al. Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. Eur J Clin Pharamacol. 2021(Oct 19). on line ahead of print.
   Google Scholar
• Melhem AL, Chourasia MK, Bigossi M, et al. Common statin intolerance variants in ABVB1 and LILRB5 show synergistic effects on statin response: an observational study using electronic health records. Frontiers Genetics. 2021;12:713181.
   PubMed Web of Science ®Google Scholar
• Sivkov A, Chernus N, Gorenkov R, et al. Relationship between genetic polymorphism of drug transporters and the efficacy of rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia. Lipids Health Dis. 2021;20(1):157.
   PubMed Web of Science ®Google Scholar
• Zubiaur P, Benedicto MD, Villapalos-García G, et al. SLCO1B1 phenotype and CYP3A5 polymorphism significantly affect atorvastatin bioavailability. J Pers Med. 2021;11(3):204–218.
   PubMed Web of Science ®Google Scholar
• Krähenbühl S, Pavik-Mezzour I, Von Eckardstein A. Unmet needs in LDL-C lowering: when statins won’t do! Drugs. 2016;76(12):1175–1190.
   PubMed Web of Science ®Google Scholar
• Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–1421.
   PubMed Web of Science ®Google Scholar
• Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep. 2013;15(1):291–298.
   PubMed Web of Science ®Google Scholar
• Abramson JD, Rosenberg HG, Jewell N, et al. Should people at low risk of cardiovascular disease take a statin? BMJ. 2013;347(oct22 3):f6123.
   PubMedGoogle Scholar
• Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther. 2008;30(11):2167–2179.
   PubMed Web of Science ®Google Scholar
• Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006;166(17):1842–1847.
   PubMedGoogle Scholar
• May HT, Knowlton KU, Anderson JL, et al. High-statin adherence over 5 years of follow-up is associated with improved cardiovascular outcomes in patients with atherosclerotic cardiovascular disease: results from the IMPRES study. Eur Heart J – Qual Care Clin Outcomes. 2021(Mar 31), Online ahead of print. DOI:https://doi.org/10.1093/ehjqcco/qcab024.
   Google Scholar
• Donnelly LA, Doney ASF, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med. 2008;25:850–855.
   PubMed Web of Science ®Google Scholar
• Diaconu CC, Iorga RA, Furtunescu F, et al. Statin intolerance: new data and further options for treatment. Curr Opin Cardiol. 2021;36:487–493.
   PubMed Web of Science ®Google Scholar
• Drexel H, Coats AJS, Spoletini I, et al. An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: barriers to be overcome. Eur Heart J Cardiovasc Pharmacother. 2020;6:115–121.
   PubMed Web of Science ®Google Scholar
• Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019 [erratum in Arterioscler Thromb Vasc Biol 2019;39:e158];39:e38–e81.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;1:1012–1022.
   Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–414.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29:1761–1770.
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630.
   PubMed Web of Science ®Google Scholar
• Ravnskov U, McCully KS, Rosch PJ. The statin-low cholesterol-cancer conundrum. QJM. 2012;105:383–388.
   PubMed Web of Science ®Google Scholar
• Shah RV, Goldfine AB. Statins and risk of new-onset diabetes mellitus. Circulation. 2012;126:e282–4.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–361.
   PubMed Web of Science ®Google Scholar
• Frayling TM. Statins and type 2 diabetes: genetic studies on target. Lancet. 2015;385:310–312.
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172:144–152.
   PubMed Web of Science ®Google Scholar
• Klimentidis YC, Arora A, Newell M, et al. Phenotypic and genetic characterization of lower LDL cholesterol and increased type 2 diabetes risk in the UK Biobank. Diabetes. 2020;69:2194–2205.
   PubMed Web of Science ®Google Scholar
• Burgess S, Timpson NJ, Ebrahim S, et al. Mendelian randomization: where are we now and where are we going? Int J Epidemiol. 2015;44:379–388.
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee HS, Wee JH, et al. Association between previous statin use and Alzheimer’s disease: a nested case-control study using a National Health Screening Cohort. Brain Sci. 2021;11:396–406.
   PubMed Web of Science ®Google Scholar
• Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation. 2006;114:2788–2797.
   PubMed Web of Science ®Google Scholar
• Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res. 2017;120:229–243.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe. A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44:467–494.
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–741.
   PubMed Web of Science ®Google Scholar
• Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2008;265:568–580.
   PubMed Web of Science ®Google Scholar
• Turner T, Stein EA. Non-statin treatments for managing LDL cholesterol and their outcomes. Clin Ther. 2015;37:2751–2769.
   PubMed Web of Science ®Google Scholar
• Greig SL, Deeks ED. Alirocumab: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2016;16:141–152.
   PubMed Web of Science ®Google Scholar
• Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events. The ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2019;73:387–396.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Bhatt DL, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Guigliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar
• Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016;18:61.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–1032.
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins of low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease. The clear wisdom randomized clinical trial. JAMA. 2019;322:1780–1788.
   PubMed Web of Science ®Google Scholar
• Bempedoic acid (Nexletol) for lowering LDL-cholesterol. Med Lett Drugs Ther. 2020;62:53–55.
   PubMedGoogle Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–1519.85.
   PubMed Web of Science ®Google Scholar
• Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. N Engl J Med. 2018; (378):e34. DOI:https://doi.org/10.1056/NEJMoa1800389.
   Google Scholar
• Camargo A, Delgado-Lista J, Garcia-Rios A, et al. Expression of proinflammatory, proatherogenic genes is reduced by the mediterranean diet in elderly people. Br J Nutr. 2012;108:500–508.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Demler OV, Sun Q, et al. Association of the Mediterranean diet with onset of diabetes in the Women’s Health Study. JAMA Network Open. 2020;3(11):e2025466.
   PubMed Web of Science ®Google Scholar
• Akesson A, Larsson SC, Discacciati A, et al. Low-risk diet and lifestyle habits in the primary prevention of myocardial infarction in men: a population-based prospective cohort study. J Am Coll Cardiol. 2014;64:1299–1306.
   PubMed Web of Science ®Google Scholar
• Chomistek AK, Chiuve SE, Eliassen AH, et al. Healthy lifestyle in the primordial prevention of cardiovascular disease among young women. J Am Coll Cardiol. 2015;65:43–51.
   PubMed Web of Science ®Google Scholar
• Lv J, Yu C, Guo Y, et al. Adherence to healthy lifestyle and cardiovascular diseases in the Chinese population. J Am Coll Cardiol. 2017;69:1116–1125.
   PubMed Web of Science ®Google Scholar
• Yang Y-L, Leu H-B, Yin W-H, et al. Adherence to healthy lifestyle improved clinical outcomes in coronary artery disease patients after coronary intervention. J Chin Med Assoc. 2021;84:596–605.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Effects of interleukin-6 inhibition with Ziltivekimab on biomarkers of inflammation among patients at high risk for atherosclerotic event. Presented at the Scientific Sessions of the American College of Cardiology, Atlanta, GA, 2021.
   Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838–1847.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
   PubMed Web of Science ®Google Scholar
• Lakshmanan S. Effect of icosapent ethyl on percent atheroma volume in patients with elevated triglycerides on statin therapy – insights from the Evaporate trial. Presented at the Scientific Sessions of the American College of Cardiology, Atlanta, GA, 2021.
   Google Scholar
• Goldenberg RM, Cheng AYY, Gilbert JD, et al. The role of icosapent ethyl in cardiovascular risk reduction. Curr Opin Cardiol. 2021;36(5):661–671. online ahead of print.
   PubMed Web of Science ®Google Scholar
• Mason RP, Eckel RH. Mechanistic insights from reduce-it strengthen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. Am J Med. 2021;134:1085–1090. online ahead of print. DOI:https://doi.org/10.1016/j.amjmed.2021.03.014.
   Google Scholar
• Fan H, Zhou J, Yuan Z. Meta-analysis comparing the effect of combined omega-3 + statin therapy versus statin therapy alone on coronary artery plaques. Am J Cardiol. 2021;151:15–24.
   PubMed Web of Science ®Google Scholar
• Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924.
   PubMed Web of Science ®Google Scholar
• Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15(12):2073–2084.
   PubMed Web of Science ®Google Scholar
• Ichikawa K, Miyoshi T, Osawa K, et al. Increased circulating malondialdehyde-modified low-density lipoprotein level is associated with high-risk plaque in coronary computed tomography angiography in patients receiving statin therapy. J Clin Med. 2021;10(7):1480–1489.
   PubMed Web of Science ®Google Scholar
• Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006;17(4):412–417.
   PubMed Web of Science ®Google Scholar
• Balling M, Nordestgaard BG, Langsted A, et al. Small dense low-density lipoprotein cholesterol predicts atherosclerotic cardiovascular disease in the Copenhagen General Population Study. J Am Coll Cardiol. 2020;75(22):2873–2875.
   PubMed Web of Science ®Google Scholar
• Fruchart J-C, Sacks FM, Hermans MP, et al. The residual risk initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res. 2008;5(4):319–335.
   PubMed Web of Science ®Google Scholar
• Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr Metab Cardiovasc Dis. 2013;23(9):799–807.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Aguiar C, Alegria E, et al. Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia. Eur Heart J. 2016;Suppl C(18):C2–C12.
   Google Scholar
• Marston NA, Giugliano RP, Melloni GEM, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis. JAMA Cardiol. 2021. on line ahead of print. DOI:https://doi.org/10.1001/jamacardio.2021.5083.
   Google Scholar
• Sniderman AD, Navar AM, Thanassoulis G. Apolipoprotein B vs low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as the primary measure of apolipoprotein B lipoprotein-related risk: the debate is over. JAMA Cardiol. 2021. on line ahead of print. DOI: https://doi.org/10.1001/jamacardio.2021.5080.
   Google Scholar
• Stone NJ, Levy RI, Fredrickson DS, et al. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation. 1974;49(3):476–488.
   PubMed Web of Science ®Google Scholar
• Mundal L, Sarancic M, Ose L, et al. Mortality among patients with familial hypercholesterolemia: a registry-based study in Norway, 1992–2010. J Am Heart Assoc. 2014;3(6):3001236.
   Web of Science ®Google Scholar
• Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J. 2008;29(21):2625–2633.
   PubMed Web of Science ®Google Scholar
• Holven KB, Narverud I, Lindvig HW, et al. Subjects with familial hypercholesterolemia are characterized by an inflammatory phenotype despite long-term intensive cholesterol lowering treatment. Atherosclerosis. 2014;233(2):561–567.
   PubMed Web of Science ®Google Scholar
• Ravnskov U, De Lorgeril M, Kendrick M, et al. Inborn coagulation factors are more important cardiovascular risk factors than high LDL-cholesterol in familial hypercholesterolemia. Med Hypotheses. 2018;121:60–63.
   PubMed Web of Science ®Google Scholar
• Alonso R, Andres E, Mata N, et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J Am Coll Cardiol. 2014;63(19):1982–1989.
   PubMed Web of Science ®Google Scholar
• Jansen ACM, Van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256(6):482–490.
   PubMed Web of Science ®Google Scholar
• Jansen ACM, Van Aalst-Cohen ES, Tanck MWT, et al. Genetic determinants of cardiovascular disease risk in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2005;25(7):1475–1481.
   PubMed Web of Science ®Google Scholar
• Burzotta F, Paciaroni K, De Stefano V, et al. G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12,034 subjects. Heart. 2004;90(1):82–86.
   PubMed Web of Science ®Google Scholar
• Ravnskov U, De Lorgeril M, Kendrick M, et al. Serious flaws in targeting LDL-C reduction in the management of cardiovascular disease in familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2021;14(3):405–406.
   PubMed Web of Science ®Google Scholar
• Chew M, Brizzell C, Abbasi K, et al. Medical journals and industry ties. BMJ. 2014;349(nov28 4):g7197.
   PubMedGoogle Scholar
• Sniderman AD, McQueen MJ, Jansen ACM, et al. Letter to the editor: a failure of standardization or a failure of the process of standardization. J Clin Lipidol. 2018;12(5):1325–1326.
   PubMed Web of Science ®Google Scholar
• De Graaf J, Couture P, Sniderman A. A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nat Clin Pract Endocrinol Metab. 2008;4(11):608–617.
   PubMedGoogle Scholar
• Sniderman M, Couture P, De Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol. 2010;6(6):335–346.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626–635.
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547–563.
   PubMed Web of Science ®Google Scholar
• Sniderman A, Langlois M, Cobbaert C. Update on apolipoprotein B. Curr Opin Lipidol. 2021;32(4):226–230.
   PubMed Web of Science ®Google Scholar
• Contois JH, Delatour V. Apolipoprotein B measurement: need for standardization. J Clin Lipidol. 2018;12(2):264–265.
   PubMed Web of Science ®Google Scholar